Drug Development Marketing White Paper 
Perficient: Drug Development
SEPTEMBER 17, 2024
This year, I’m particularly excited about how far we’ve advanced with Optimizely One in collaboration with Perficient, which is described as an operating system for marketing teams. Many organizations are shifting away from piecing together various products to build their marketing technology systems. Will you be at Opticon 2024?
PPD
FEBRUARY 10, 2025
In the past, these developers mostly used in-house resources for their clinical monitoring and site management capabilities, whereas today they often prefer functional service provider (FSP) or full-service outsourcing (FSO) models, or a hybrid of the two, to ensure on-time and on-budget delivery of clinical operations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Conversations in Drug Development Trends
APRIL 4, 2024
Global Impact of ICH M10 Validation Guidelines Harmonization of bioanalytical validation methods is crucial in a world where pharmaceuticals are developed and approved across different regions. The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies.
PPD
AUGUST 28, 2024
For pharmaceutical innovators and drug developers working to bring oncology therapies to market, patients are the “why” behind it all. Drug developers must consider ways to remove these barriers to enhance their ability to recruit and retain trial participants.
Conversations in Drug Development Trends
DECEMBER 20, 2023
You can learn more about biomarkers and how to use them in oncology studies in this white paper. Optimize Your Oncology Program with Worldwide Matt Cooper and our global team of oncology experts have dedicated their careers to oncology clinical development programs.
PPD
OCTOBER 2, 2024
A recent white paper from the PPD™ clinical research business of Thermo Fisher Scientific details how these functions have evolved over the years, moving from capabilities that were previously built up and maintained in-house, to the multiple outsourcing models available today.
Conversations in Drug Development Trends
MARCH 7, 2024
When conducting first-in-human (FIH) clinical trials, small to midsize pharmaceutical and biotechnology companies are faced with several crucial choices that can shape the trajectory of their drug development pathway. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.
Expert insights. Personalized for you.
109 
Let's personalize your content